Drugs / Linaprazan glurate
Linaprazan glurate
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03105375 | Feb → Oct 2017 | — | Cinclus Pharma Holding AB | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07308041 | Nov → Dec 2025 | gastroesophageal reflux disease | Cinclus Pharma Holding AB | Completed | No outcome recorded |
| Phase 1 | NCT07294846 | Sep → Dec 2025 | — | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05469854 | Jul 2022 → Nov 2026 expected | gastroesophageal reflux disease | Cinclus Pharma Holding AB | Recruiting | No outcome recorded |
| Phase 1 | NCT07107672 | Jun → Jul 2022 | gastroesophageal reflux disease | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04293965 | Oct 2018 → Sep 2019 | — | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05055128 | Aug 2021 → Sep 2022 | esophagitis | Cinclus Pharma Holding AB | Completed | No outcome recorded |
| Phase 2 | NCT04531475 | Jan → Oct 2020 | peptic esophagitis | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07079540 | Jun 2021 → Jul 2022 | peptic esophagitis | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Linaprazan glurate | “Linaprazan glurate, a potassium-competitive acid blocker, is in development for the treatment of erosive oesophagitis and other acid-related diseases.” PMID 40183130 ↗ Apr 20253“The participants will then continue to take linaprazan glurate (Day 2 to Day 8).” NCT07308041 ↗ |
| Known as | Glurate de linaprazan | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095187 ↗ |
| Known as | Glurato de linaprazan | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095187 ↗ |
| Known as | X842 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04531475 ↗ |
| Modality | Small molecule | — CHEMBL5095187 ↗ |
| Route | Oral | “X842 50 mg, capsule, orally, once daily” NCT04531475 ↗ |